ADC THERAPEUTICS SA
NYSE: ADCT (ADC Therapeutics SA)
Kemas kini terakhir: 3 jam lalu0.996
-0.05 (-5.11%)
| Penutupan Terdahulu | 1.05 |
| Buka | 1.07 |
| Jumlah Dagangan | 1,282,520 |
| Purata Dagangan (3B) | 1,649,895 |
| Modal Pasaran | 126,720,552 |
| Harga / Jualan (P/S) | 1.86 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| Margin Keuntungan | -197.64% |
| Margin Operasi (TTM) | -123.58% |
| EPS Cair (TTM) | -1.42 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 27.60% |
| Nisbah Semasa (MRQ) | 4.46 |
| Aliran Tunai Operasi (OCF TTM) | -136.07 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.34 M |
| Pulangan Atas Aset (ROA TTM) | -27.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | ADC Therapeutics SA | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.70 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.58% |
| % Dimiliki oleh Institusi | 66.89% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tcg Crossover Management, Llc | 31 Mar 2026 | 11,390,175 |
| Prosight Management, Lp | 31 Mar 2026 | 8,300,000 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| AZELBY ROBERT | - | 3.08 | -12,600 | -38,808 |
| BIZZARI JEAN-PIERRE | - | 3.08 | -12,600 | -38,808 |
| COUGHLIN TIMOTHY | - | 3.08 | -12,600 | -38,808 |
| HUG PETER | - | 3.08 | -2,156 | -6,640 |
| MONGES VIVIANE | - | 3.08 | -2,596 | -7,996 |
| SANDOR VICTOR | - | 3.08 | -12,600 | -38,808 |
| SQUARER RON | - | 3.08 | -15,196 | -46,804 |
| Jumlah Keseluruhan Kuantiti Bersih | -70,348 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -216,672 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 3.08 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| COUGHLIN TIMOTHY | Pengarah | 03 Jun 2026 | Dibuang (-) | 12,600 | 3.08 | 38,808 |
| BIZZARI JEAN-PIERRE | Pengarah | 03 Jun 2026 | Dibuang (-) | 12,600 | 3.08 | 38,808 |
| HUG PETER | Pengarah | 03 Jun 2026 | Dibuang (-) | 2,156 | 3.08 | 6,640 |
| MONGES VIVIANE | Pengarah | 03 Jun 2026 | Dibuang (-) | 2,596 | 3.08 | 7,996 |
| SANDOR VICTOR | Pengarah | 03 Jun 2026 | Dibuang (-) | 12,600 | 3.08 | 38,808 |
| SQUARER RON | Pengarah | 03 Jun 2026 | Dibuang (-) | 15,196 | 3.08 | 46,804 |
| AZELBY ROBERT | Pengarah | 03 Jun 2026 | Dibuang (-) | 12,600 | 3.08 | 38,808 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |